Kaigo Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kaigo Health (YC F25) deploys AI voice agents for elderly outpatient follow-up, scaling post-visit check-ins 100x for Medicare providers who currently have near-zero between-visit care.
About
Kaigo Health is a healthcare AI startup founded in 2025 and headquartered in San Francisco, built to address one of the most persistent gaps in outpatient elderly care: the near-complete absence of structured follow-up between clinical visits. The company was accepted into Y Combinator's Fall 2025 batch, a validation of its founding team and market thesis at a very early stage. Kaigo targets the Medicare provider ecosystem, where outpatient follow-up is both a quality metric and a reimbursement driver under value-based care arrangements.\n\nKaigo's platform deploys AI voice agents that conduct follow-up calls with elderly patients between clinical encounters, checking on medication adherence, symptom changes, and overall wellbeing in a conversational, accessible format appropriate for older adults who may be less comfortable with app-based or text communication. The system scales these follow-up touchpoints by 100x compared to what a human care coordination team could accomplish at equivalent cost, dramatically expanding the reach of providers who want to improve patient engagement without proportional staffing increases.\n\nThe company is entering a market shaped by twin pressures: an aging US population driving record Medicare enrollment and a care workforce shortage that makes scaling high-touch care coordination through humans alone economically unsustainable. AI voice agents are increasingly recognized as a practical solution to this gap, particularly for the elderly population where voice interaction is natural and phone calls remain a trusted communication channel. Kaigo's early YC backing positions it alongside a cohort of companies building AI infrastructure for the future of value-based elder care.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.